ACTA will be holding a series of virtual clinics on Adaptive Platform Trials this year (subject to demand). For those who are keen to present their work, this will be a 15 min virtual presentation + 15 min panel discussion targeted at groups who are considering or planning an adaptive platform trial (early stages preferable).
If you are keen to present, please submit 3-4 lines on your trial to email@example.com.
We welcome those interested to learn more in this space and would like to attend these presentations.
Below is the registration link for those who are keen to attend and/or present.
Confirmed dates and times for next session:
9th November (Thursday), 3-4pm (AEST)
Prof Dan Siskind
SWiMS – Schizophrenia, Weight, Metformin and Semaglutide
Antipsychotics are the mainstay of treatment for schizophrenia. However, antipsychotics are linked with obesity and diabetes, which increases the risk of heart disease. Preliminary research suggests the diabetes drugs semaglutide and metformin can reduce antipsychotic-related obesity. The team will undertake a national clinical trial to establish the role of semaglutide and metformin in reducing weight among obese people taking antipsychotics.
Prof Siskind trained as a psychiatrist in Australia and the United States. He works clinically as a psychiatrist in Brisbane, Australia with people with treatment refractory schizophrenia. His research interests include treatment refractory schizophrenia, clozapine and the physical health comorbidities associated with schizophrenia. He has over 230 publications and over $44million in competitive research grants, with over $6million as CIA.
9th March (Thursday), 3-4pm (AEST): Dr Brendan Smyth and Dr Jessica Schults (on behalf of Prof Claire Rickard)
Please note that these sessions will be recorded. If you do not wish to be on screen, please ensure your video is turned off and your questions are sent through the chat box.
For more information, please contact us at firstname.lastname@example.org